Welcome to our dedicated page for Hinge Health SEC filings (Ticker: HNGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Hinge Health, Inc. (NYSE: HNGE) SEC filings, giving investors and researchers a primary source for the company’s regulatory disclosures. As a public company in the healthcare and health information services space, Hinge Health uses its filings to report financial results, describe material events, and document key corporate actions.
Current and prospective shareholders can review periodic reports and current reports on Form 8-K that summarize important developments. Recent 8-K filings have covered topics such as quarterly financial results, the use of non-GAAP financial measures, and the authorization of a share repurchase program for the company’s Class A common stock. These filings often reference accompanying press releases that provide detailed financial statements, reconciliations of non-GAAP metrics, and information about earnings conference calls.
Other 8-K disclosures describe events related to the company’s initial public offering, including lock-up agreements that restrict the sale or transfer of shares for a defined period and the conditions under which certain shares become eligible for earlier release. Such filings help investors understand share supply dynamics, insider selling restrictions, and the timing of potential changes in the public float.
Through its SEC reports, Hinge Health also explains how it presents metrics like calculated billings and discusses the seasonality associated with client launches and platform access. These documents complement the company’s press releases about its AI-powered musculoskeletal care platform, wearable devices, and clinician-supported programs by providing audited or reviewed financial data and formal regulatory context.
On Stock Titan, SEC filings for HNGE are updated as they are posted to the EDGAR system. AI-powered tools can help summarize lengthy documents, highlight key figures, and surface important sections, such as discussions of results of operations, share repurchase details, and other material events disclosed in Hinge Health’s filings.
Insight Venture Partners affiliates, identified as a director and 10% owner of Hinge Health, Inc. (HNGE), reported on Form 4 that on December 1, 2025 they converted multiple blocks of Class B Common Stock into Class A Common Stock and then sold those Class A shares.
The reporting persons converted and sold 826,216, 19,659, 677,508 and 131,057 shares of Class B/Class A stock, respectively, through affiliated Insight investment funds, with each corresponding Class A position shown as reduced to zero following the sales at a reported price of $47.76 per share.
Footnotes describe that each share of Class B Common Stock was convertible into one share of Class A Common Stock and outline Insight’s fund and holding-company structure, noting that various Insight entities and managers may be deemed to share voting and dispositive power over these Hinge Health shares while generally disclaiming beneficial ownership beyond their pecuniary interests.
HNGE filed a notice under Rule 144 for a proposed sale of restricted or control securities. The filing covers the planned sale of 19,659 shares of Class A stock through broker Merrill Lynch, with an aggregate market value of 961,521.69. These shares are part of a larger base of 37,919,155 shares outstanding and are expected to be sold on the NYSE on or about 12/01/2025. The seller originally acquired the 19,659 Class A shares from the issuer in a private placement on 07/03/2018, paying cash at that time.
HNGE has a shareholder planning to sell 131,057 Class A shares through Merrill Lynch on the NYSE, with an aggregate market value of $6,409,997.87. The filing notes that 37,919,155 shares of this class are outstanding. The shares to be sold were originally acquired from the issuer in a private placement on 07/03/2018 for cash.
HNGE has a shareholder filing a Form 144 notice to sell up to 677,508 Class A shares through Merrill Lynch on the NYSE, with an approximate aggregate market value of $33,136,916.28. The filing notes that there were 37,919,155 shares of this class outstanding when the notice was prepared and that the proposed sales may begin on 12/01/2025. The shares were originally acquired from the issuer in a private placement on 07/03/2018 and paid for in cash.
HNGE reported that a holder of its Class A stock has filed a notice of proposed sale under Rule 144. The holder plans to sell 826,216 Class A shares through Merrill Lynch on the NYSE, with an approximate sale date of 12/01/2025. The filing lists an aggregate market value for these shares of $40,410,224.56. These Class A shares were originally acquired from the issuer in a private placement on 07/03/2018 and paid for in cash. The notice also states that 37,919,155 shares of this class were outstanding, providing a baseline for the size of the proposed sale.
Hinge Health, Inc. reported an insider equity transaction by its President on 12/01/2025. The filing shows that 5,126 shares of Class A common stock were disposed of in a transaction coded "F" at a price of $48.91 per share. This type of code indicates shares were withheld or surrendered to cover taxes associated with the vesting of restricted stock units, rather than being sold on the open market.
After this tax-related share cancellation, the reporting officer beneficially owns 784,776 shares of Class A common stock directly. The issuer satisfied the related federal and state tax withholding obligations in exchange for the relinquished shares, leaving the executive with a substantial continuing equity stake in the company.
Hinge Health, Inc.'s Chief Financial Officer reported a routine share disposition related to tax withholding on equity compensation. On 12/01/2025, the reporting person disposed of 8,213 shares of Class A common stock at $48.91 per share in an exempt transaction. After this transaction, the officer beneficially owned 471,665 shares directly.
The company explains that the shares were withheld and cancelled by the issuer to cover federal and state tax obligations arising from the vesting of restricted stock units, as permitted under Section 16b-3(e). This reflects standard administrative handling of equity awards rather than an open-market sale.
HNGE shareholder(s) filed a Form 144 notice to sell Class A common stock. The filing covers a proposed sale of 21,757 Class A shares through Merrill Lynch, with an aggregate market value of 1,088,937.85. The shares relate to a private placement acquisition on 02/04/2020, paid for in cash.
The filing notes that 37,919,155 Class A shares were outstanding at the time of the notice. It also discloses recent sales by affiliated Bessemer Venture Partners funds in November 2025, including blocks of 373,955, 103,160, 351,045 and 96,840 Class A shares, with individual transaction gross proceeds between 4,674,466.8 and 14,976,898. The seller represents they are not aware of undisclosed material adverse information about HNGE.
HNGE has a Form 144 notice indicating that a stockholder plans to sell 23,176 shares of Class A common stock through Merrill Lynch on the NYSE, with an approximate sale date of 11/28/2025. The aggregate market value of the shares to be sold is listed as 1,159,958.8, and the total number of Class A shares outstanding is shown as 37,919,155.
The shares to be sold were acquired on 02/04/2020 in a private placement from the issuer for cash. Over the past three months, Bessemer Venture Partners X LP and Bessemer Venture Partners X Institutional LP together sold several Class A share blocks, including 373,955 and 103,160 shares for gross proceeds of 14,976,898 and 4,979,533.2, and 351,045 and 96,840 shares for gross proceeds of 14,059,352 and 4,674,466.8.
Hinge Health, Inc. (HNGE) Chief Financial Officer James Budge reported open-market sales of Class A common stock under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2025. On November 25, 2025, he sold 15,730 shares at a weighted average price of $46.8822, 27,248 shares at a weighted average price of $47.7669, and 1,611 shares at a weighted average price of $48.2738, across specified price ranges. Following these transactions, Budge beneficially owned 479,878 shares of Hinge Health Class A common stock in direct ownership.